US Patent Issued to ZOMAGEN BIOSCIENCES on Nov. 11 for "N-((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)carbamoyl)-4, 5, 6, 7-tetrahydrobenzofuran-2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (MS)" (California Inventors)

Posted On: 2025-11-11

ALEXANDRIA, Va., Nov. 11 -- United States Patent no. 12,466,800, issued on Nov. 11, was assigned to ZOMAGEN BIOSCIENCES LTD (Encinitas, Calif.).

"N-((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)carbamoyl)-4, 5, 6, 7-tetrahydrobenzofuran-2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (MS)" was invented by Raju Mohan (Encinitas, Calif.), John Nuss (Encinitas, Calif.), Jason Harris (Encinitas, Calif.) and Shendong Yuan (Encinitas, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Described herein are N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl) carbamoyl)-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide derivatives and related compounds of formula (I) wherein R1 ...

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

US Patent Issued to ZOMAGEN BIOSCIENCES on Nov. 11 for "N-((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)carbamoyl)-4, 5, 6, 7-tetrahydrobenzofuran-2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (MS)" (California Inventors)